Riociguat for the treatment of pulmonary arterial hypertension. - Test2 - elhamkhani - TriplyDB

Riociguat for the treatment of pulmonary arterial hypertension.

Riociguat for the treatment of pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q33163083

about

5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure Guanylate cyclase stimulators for pulmonary hypertension The impact of genome-wide association studies on the pathophysiology and therapy of cardiovascular disease Pulmonary hypertension in patients with heart failure and preserved ejection fraction: differential diagnosis and management Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle Disorders Redox biology in pulmonary arterial hypertension (2013 Grover Conference Series)The limits of oral therapy in pulmonary arterial hypertension management Pharmacology and Clinical Drug Candidates in Redox Medicine Medical treatment update on pulmonary arterial hypertension Pulmonary hypertension: diagnostic and therapeutic challenges The molecular targets of approved treatments for pulmonary arterial hypertension Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma Drug treatment of pulmonary hypertension in children New insights into the role of soluble guanylate cyclase in blood pressure regulation Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction Reactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical Indications Riociguat reduces infarct size and post-infarct heart failure in mouse hearts: insights from MRI/PET imaging Interfacial residues promote an optimal alignment of the catalytic center in human soluble guanylate cyclase: heterodimerization is required but not sufficient for activity.A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives Recent advances in the management of pulmonary arterial hypertension Treatment-related biomarkers in pulmonary hypertension Hemodynamics should be the primary approach to diagnosing, following, and managing pulmonary arterial hypertension Pulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome: current practice in pediatrics Pulmonary Hypertension in Children.Functional Characterization of the GUCY1A3 Coronary Artery Disease Risk Locus.Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue Pulmonary hypertension and right heart dysfunction in chronic lung disease.Novel Analysis of the Oral Treprostinil Combination Therapy Trial Data.Pediatric pulmonary arterial hypertension.Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.The Changing Landscape of Pulmonary Arterial Hypertension in the Adult with Congenital Heart Disease.Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials.Update in pulmonary vascular diseases 2013.Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension Identifying "super responders" in pulmonary arterial hypertension.The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension.Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension

P2860

Q21284504-94979742-20DB-4DF5-BF11-24F85366D0D5 Q26470534-4442C9F0-2806-4A94-9F49-4B36476FDFBF Q26748869-0CE0B81D-B06F-4CC9-AAB9-BA9F24E72EEF Q26750994-610EC4A5-DBC8-4EDD-AE00-B302D195033A Q26753129-B2540D1E-C41A-440B-9943-8FE85D343416 Q26772286-94AC8202-D7E3-49CE-8E52-0BBBC8F1962A Q26773209-2B431C5C-FA59-4599-AED0-F39B97A01A1D Q26785525-698387BB-ABA8-46A5-8BD6-F80AFC94C40A Q26785995-42E777EA-928C-42D9-9898-C8FDFE8C4831 Q26796434-C8CC8B77-7D46-4CF7-95CA-D0C1C66AA77C Q26798308-F27D31A9-BC09-4A68-BB11-2FE88BBC9129 Q26861763-2AAD9A4E-F030-4B38-8E46-27A822BA96C6 Q26996078-838E2FDD-9250-48CB-AB8E-EE465A789BBD Q27021422-18B9759E-0BC9-4451-B69D-C439F229B372 Q27021649-12CFCB5D-1BED-435F-80B4-754D349E1038 Q27023074-F3C30C24-0907-48CB-AD65-023F559E019B Q27024279-4A5098A9-0E21-4F6E-B01A-B021418E1739 Q27024762-24B1B0B3-1894-426D-AB59-7C14BE2901A0 Q27336286-ED68F75D-0F3C-4200-B2CA-52B63B60D7FB Q27682500-415879E1-1EB2-45EF-9FA4-33E82F5842E1 Q28072562-6919992D-BCEA-4878-939C-D2A77302448B Q28073063-5335FBE5-C65C-4AC8-9BFD-01F084AA608C Q28075707-1251F48A-B1A0-4A7C-BF39-0DB7C678E077 Q28081276-8C5EDA12-6889-4A6B-8B5A-01E31526769B Q28083099-E3F37DE6-8AA3-4A68-8BAB-D95AC0C7BB12 Q28085572-DAAA88B0-787E-4490-9A02-6F832E1CB821 Q30248871-8E7B8E91-6815-4F03-ACDE-A8FFE83C0125 Q30252419-2987C23A-003D-40B7-9DF4-E9920C01E884 Q30316523-CF401224-8948-41C6-9576-3C9AD45BCDF5 Q30432299-80225543-24A9-42AD-8EB8-9B32F1729369 Q31108228-89844F52-8660-4A82-B3CE-33FA5C3B6AD6 Q33163446-EBC14F6E-E2E9-4653-B681-F6DA0B9D839D Q33596457-05EFEDB0-051E-4FD1-85B3-CC2132384322 Q33608215-68C439BF-72DC-4809-9DFF-3291011F547A Q33673947-6C56C130-2F0D-421E-B486-A1AFD75EEC66 Q33732209-8BD6B6A9-DCF7-4B4C-A869-1B3FD500F627 Q33759804-466BC0F7-6718-4438-97CB-114442BD95D4 Q33788452-03978D9A-892F-40AC-9814-B752F21AE42B Q33788554-558131A8-0165-40B6-94B2-F6C6615B076C Q33788560-4416A7AB-33E7-4920-8E67-639228A71840

P2860

Riociguat for the treatment of pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q33163083

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Riociguat for the treatment of pulmonary arterial hypertension.

@ast

Riociguat for the treatment of pulmonary arterial hypertension.

@en

type

label

Riociguat for the treatment of pulmonary arterial hypertension.

@ast

Riociguat for the treatment of pulmonary arterial hypertension.

@en

prefLabel

Riociguat for the treatment of pulmonary arterial hypertension.

@ast

Riociguat for the treatment of pulmonary arterial hypertension.

@en

P1433

Q33163083-5953654A-25E3-4778-955A-8BE49F410A22

P1476

Q33163083-498D73CF-3BA9-4B18-8B19-B7B46EC0D786

P2093

Q33163083-07789570-ADA2-4CAE-B9EE-84D79E10F32E

Q33163083-0E4324EF-8B0C-4E86-850F-E5F7FADA4A1C

Q33163083-1F381A8C-F523-427B-A56E-4256EA5B96FB

Q33163083-24831167-B4E8-4118-8C68-5266424AEEED

Q33163083-316CE8F5-24BE-43EC-9A98-38E6D184F446

Q33163083-3CF27DA5-249C-4676-8919-CE633C7A967B

Q33163083-583DC6FF-58E5-498E-8D14-BCB0B9761A61

Q33163083-85C11539-6EC4-4299-AC50-C2F610BB5CB5

Q33163083-A05C063C-E336-4786-AAAA-733E5F2363EF

Q33163083-C8D9386A-12DE-4354-A68D-90E73BB4EAA7

P304

Q33163083-777789FA-0A63-4076-8172-0AF2905FB08E

P31

Q33163083-154AC2B6-1A93-4A0E-A832-B53F53E6F222

P356

Q33163083-A4840415-50D8-4DF2-A962-93374ACC4CF5

P407

Q33163083-1A4ABFC6-9B43-4110-8354-D51DE131D2A7

P433

Q33163083-C6352FBF-D3A4-458F-83A7-3D4136EE3D99

P478

Q33163083-848B0585-7A00-43E9-BFFF-3D5E78DD034C

P50

Q33163083-5CE0F2C9-751A-4261-A53C-61CD75ADA349

Q33163083-6D8B9E73-89CA-495C-8EE0-E4378E896AD7

P577

Q33163083-6BDF6A34-2B60-411A-85A6-4DDA78FA4012

P698

Q33163083-D497690C-EB6F-4807-AA28-AE8F3144EBAB

P921

Q33163083-E8A9D16D-953B-4943-9FFB-556EC200B2A5

P356

P1433

The New England Journal of Medicine

P1476

Riociguat for the treatment of pulmonary arterial hypertension.

@en

P2093

Anne M Keogh

http://www.w3.org/2001/XMLSchema#string

Arno Fritsch

http://www.w3.org/2001/XMLSchema#string

David Langleben

http://www.w3.org/2001/XMLSchema#string

Dieter Neuser

http://www.w3.org/2001/XMLSchema#string

Ekkehard Grünig

http://www.w3.org/2001/XMLSchema#string

Hossein-Ardeschir Ghofrani

http://www.w3.org/2001/XMLSchema#string

Lewis J Rubin

http://www.w3.org/2001/XMLSchema#string

Michael Ochan Kilama

http://www.w3.org/2001/XMLSchema#string

Nazzareno Galiè

http://www.w3.org/2001/XMLSchema#string

PATENT-1 Study Group

http://www.w3.org/2001/XMLSchema#string

P304

330-340

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1209655

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

369

http://www.w3.org/2001/XMLSchema#string

P50

Friedrich Grimminger

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23883378

http://www.w3.org/2001/XMLSchema#string

P921